Moreover, we have previously demonstrated that CAIX full-length percentage (CAIX FL%) of the total CAIX mRNA can be identified in the urine sediment of patients with urological cancers and can serve as a non-invasive biomarker for prostate, bladder and kidney tumors [24,27]. Here, CA9 is linked to kidney neoplasm.